Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Internal Medicine 2022, 182: 179-184. PMID: 34846533, PMCID: PMC8634151, DOI: 10.1001/jamainternmed.2021.7382.Peer-Reviewed Original ResearchMeSH KeywordsAdultBNT162 VaccineCase-Control StudiesComparative Effectiveness ResearchCOVID-19COVID-19 VaccinesFemaleHumansIncidenceMaleRetrospective StudiesSARS-CoV-2Time FactorsConceptsSARS-CoV-2Maccabi Healthcare ServicesBooster doseBNT162b2 vaccineMRNA vaccinesPositive SARS-CoV-2 polymerase chain reaction testSARS-CoV-2 polymerase chain reaction testPreliminary retrospective case–control studyRetrospective case-control studyPositive PCR test resultsBNT162b2 mRNA vaccineVaccine-derived protectionTest-negative designDuration of immunityCase-control studyPolymerase chain reaction testEstimated odds ratioHealthcare servicesCase-control analysisPCR test resultsPositive test resultsChain reaction testCase-control designTesting PositiveOdds ratio